AIT gains FDA nod for imaging/biopsy system:
This article was originally published in Clinica
Executive Summary
Advanced Imaging Technologies (AIT) has gained US FDA 510(k) clearance for a breast biopsy capability on its Avera breast imaging system. The new indication will allow physicians to perform immediate biopsies on suspicious breast masses during an Avera imaging session, as the patient does not have to move from their position, says the Preston, Washington firm. Additionally, the biopsy procedure can be performed sooner; sometimes the period between mass detection and biopsy can be several days, says AIT.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.